UMIP and MEC co-sponsors and exhibitors at Educate North Conference and Awards 2016

Written by UMIP on . Posted in News

On 21st April, UMIP and Manchester Enterprise Centre (MEC) exhibited at the Educate North Conference and Awards as one of the key event sponsors alongside the Telegraph Group and Barclays. The event was organised by Carm Productions’ Rob McLoughlin and Prolific North’s Nick Jaspan.

Held at the Hilton Hotel, the aim of the conference was to inform attendees about the sheer scale and investment taking place at Universities and higher education across the North and the ways in which attendees might engage with said institutions in terms of commercial engagement.

We exhibited four University of Manchester innovations which included our EasyCare Cotton technology, illustrated by a pair of Levis jeans, a 3M respirator cartridge containing PIMs technology and two graphene-based technologies: a flexible, transparent, conductive screen which powered an LED and a conductive graphene ink printed onto a University of Manchester T-shirt which played sounds when motion above was detected.

The event marked the launch of the University Entrepreneurs Challenge 2016 which saw six student companies from Northern universities or HE institutions go head to head in a special showcase which demonstrated the range, diversity and ingenuity of entrepreneurs emerging from our institutions. Four of the six finalists were University of Manchester alumni and included Amy Win – 4 Lunch,  Dr Daniel Jamieson – Biorelate, Paul Delamere – Shindigger Brewing Company and Christina Taylor -The Aim Sky High Company.

The awards were judged by a number of leading industry experts and professionals including Martin Henery from Manchester Enterprise Centre. Martin comments: “As good as our 4 finalists from The University of Manchester were, they were up against some stiff competition which made the task that much more difficult for the judges. The discussion in the judges’ chamber was an interesting and lively one but one thing we were all agreed upon was the quality of the presentations and the confidence and passion of the individuals making them. Whether their respective businesses succeed or fail, one thing is for sure, they are all individuals to watch and are certain to make their mark.”

First prize of £5,000 was secured by University of Chester start–up Heritage with 4 Lunch and The Aim Sky High Company securing 2nd and 3rd places respectively with prizes of £3,000 and £2,000.

Amy Win, founder of 4Lunch, comments: “It was great to be recognised at the event for my work with 4Lunch. The University of Manchester provided me with fantastic advice at the start of my entrepreneurial journey and continue to support my endeavours still now, three years after I graduated.”

Congratulations also go to Policy@Manchester who won the External Relations of the Year category.

Over 250 people attended the evening awards ceremony and, with 14 categories ranging from Lecturer of the Year to Research Team of the Year, it was a great celebration of the outstanding teams and people behind further and higher education institutions’ initiatives across the North.

Amy Win - 4lunch

Amy Win – 4lunch

Christina Taylor – The Aim Sky High Company

 

 

 

 

 

 

 

 

For a full list of awards, please see here

Graphene Patenting

Written by UMIP on . Posted in News

Some people have been curious as to why The University of Manchester didn’t patent graphene. Clive Rowland, CEO of UMI3, responds.

The University of Manchester neither discovered nor invented graphene; rather it was the place where this amazing material was first isolated from graphite in 2003. Graphene had been known about for decades before the Manchester achievement.

That initial isolation approach ( using Scotch® tape ) is the rudimentary basis of one way of making graphene, known as mechanical exfoliation.

Mechanical exfoliation as a ‘production’ method was not novel as a concept. Teams elsewhere had used this gradual removal technique as a way of obtaining thin films before Manchester. For example, in 1990, Heinrich Kurz ( Aachen University) reported peeling optically thin layers with transparent tape so that his group could study the dynamics of graphite material.

So a ‘fundamental broad patent’ wasn’t on the cards because, to acquire a patent, among other things, it has to show novelty. In fact graphene patenting started in 1969 when the use of monolayer graphene was patented. Other graphene patents were filed between then and 2004.

What was exceptional and breakthrough at Manchester ( ‘Graphene Rediscovered in its New Incarnation’ as André Geim has said ) was the size of graphene obtained which allowed Geim and Novoselov to experiment, tune, measure and report the electronic properties of graphene. That was what ultimately captured the attention of researchers worldwide.

We had hoped that we could patent our high-frequency electronic graphene devices as the basis. Patent attorneys agreed and drafted a patent in 2003 based on the first draft of the ‘Science’ paper and it was examined. Unfortunately possibilities for getting such a patent granted were ‘dead in the water’, even without challenges. US patents filed before completely anticipated our patent proposal ( none of those have been commercialised yet ).

André Geim had consulted a major chip manufacturer too and, given his concern for good use of taxpayers’ money, the resultant outcome was that he did not support a patent filing. This was a ‘good call’ as there still seems no prospect of graphene-based electronics for 10 years or more – maybe never as other ‘sister’ two-dimensional materials appear to be better prospects for this purpose.

Negative feedback ( twice ) from a leading journal – “no sufficient scientific advance” – ( though later published in Science ) and zero commercial uptake of our general promotional activities and our confidential graphene proposals at that time didn’t do anything for its case either.

Even if there had been a ‘broad’ patenting opportunity, in the absence of industry or investor interest, universities’ practice is to file in very limited territories, often just in the home country. Frequently they are made open source for a nominal fee or free.

Located in Silicon Valley, Stanford University’s ‘biggest’ inventions – Google and DNA Cloning – were filed as patents in the US only.

Now there are many ways to make graphene – completely different from mechanical means. All need more time to ‘market-validate’ their mass production capabilities and evidence the chances for a return on investment.

Very early patents taken out on all of these approaches are likely to have modest and declining value because methods are evolving all of the time and some processes will be suitable for some applications but not others ……and the patent protection clock is forever winding down.

Whilst we were continuously looking for opportunities since the isolation, it wasn’t until 2009 that invention disclosures took off. This is when reduced graphene oxide – an exciting opportunity for synthesising graphene on a bulk scale – was ‘rediscovered’ (by others) – it had originally been isolated and identified as monolayers in 1962.

So we couldn’t have cornered the graphene market in 2003/4. There wasn’t a defensible or even credible broad patent position; it wouldn’t have been filed internationally; keeping experimental results secret for years isn’t an option for bodies with charity status like universities nor is that appropriate; many other routes to making graphene are possible; and we didn’t want to speculate with taxpayers’ money by trying to buy up the world’s graphite mines either.

More on this subject can be found in André Geim’s ‘Prehistory of Graphene’ ( Physica Scripta, 2012, Volume T146).

University’s blindness therapy comes a step closer following landmark licensing deal with US firm

Written by UMIP on . Posted in News

eye shotHundreds of thousands of people worldwide, who have a disease that can lead to blindness, could have their sight restored after The University of Manchester entered into a technology license with Seattle-based company Acucela Inc.

The agreement will see Acucela commercialise technology developed by researchers at The University of Manchester that has the potential to partially restore vision in people who are blind from degenerative retinal conditions such as Retinitis Pigmentosa (RP).

RP is an inherited retinal disease that causes a progressive degeneration of the photoreceptor cells in the eye. Often beginning in childhood, RP patients most commonly first experience difficulties with peripheral and night vision, followed by poor colour perception and central vision; in many sufferers this can eventually result in legal blindness. RP affects approximately 1 out of every 4,000 people in the US, Europe and Asia, around 1.5M people in total, and there is currently no effective treatment for this disorder.

Acucela, a clinical-stage ophthalmology company that specialises in developing treatments to slow the progression of sight-threatening diseases of the eye, will now undertake a programme of clinical trials ahead of commercialisation of the technology. It is anticipated that the first patients will be treated within 3 years and Acucela plans to evaluate the ability of the therapy to partially restore vision in patients who are legally blind.

The therapy was developed by University of Manchester researchers Dr. Jasmina Cehajic-Kapetanovic and Professors Robert Lucas and Paul Bishop. In advanced RP the photoreceptor (light-sensitive) cells die off, but other neuronal cells are still present in the retina. In trials using RP affected mice with a complete loss of their photoreceptor cells, the scientists used a gene therapy approach which successfully made these other cells light-responsive. This optogenetic therapy was sufficiently effective at restoring visional responses in the mice to allow them to detect spatial patterns presented using an ordinary flat screen display.

Commenting on the license arrangement Dr. Ryo Kubota, MD, PhD, and Chairman, President and CEO of Acucela said: “We are extremely excited to enter into this collaboration with the University and to begin the important development work needed to unlock the potential of optogenetic gene therapy to improve visual function in patients who have lost much of their vision as well as their hope.”

Dr. Paul Bishop, FRCOphth, PhD, Professor of Ophthalmology, University of Manchester added: “This is a very exciting therapeutic approach as the blind mice we treated could see surprisingly well in normal lighting conditions, and we think the approach may be safe as we are putting a normal human retinal protein back into the retina, but in cells that don’t normally make it. We are delighted at the prospect of working with Acucela towards restoring some visual function in patients who have severe visual loss from RP and similar conditions.”

The agreement was negotiated on behalf of the University by its technology transfer office, UMIP. Director of Operations at UMIP, Dr. Rich Ferrie commented, “We believe that Acucela is the ideal partner to develop a gene therapy for RP based on this ground-breaking science. The licensing arrangement has the potential to deliver significant economic return to the University if the clinical trials and commercialisation programme are successful. More importantly the signing of this agreement represents a potentially pivotal moment and offers real hope for millions of RP patients around the world.”

The technology was first reported in Current Biology in June 2015 and in The New Scientist in August 2015 and it was also presented at the ARVO eye research conference in the US in May 2015.

Professor Paul Bishop

Professor Paul Bishop

Campus Entrepreneurs Moving the Gender Balance in the Right Direction

Written by UMIP on . Posted in News

Layout 1There has been a lot of debate recently around female entrepreneurship and the reasons why there are so few women in technology. Here at The University of Manchester we have seen quite the opposite and hope that our activities are supporting a reversal of this trend, and give rise to an increase in not just female led technology companies but ones right across the board.

“In conjunction with our partners we have been driving a number of support activities that have seen an incredible response from our female entrepreneurs with ideas for campus start-ups seeking support. We want to stimulate more gender and minority balance in our businesses. Studies show that companies with different points of view, market insights and approaches to problem solving have higher sales, more customers and larger market share than their less-diverse rivals1,” said Tony Walker Director of UMIP’s Innovation Optimiser.

In conjunction with Manchester Enterprise Centre, we have been working closely with social entrepreneur support network  UnLtd, stimulating social start-ups based on campus and hosting  the Women Supporting Women Social Entrepreneurs (WSSE)  a network of like-minded women from across Greater Manchester, operating across the North West, who use their collective energies to support each other to support other female social entrepreneurs. Nickala Torkington, Partnership Manager at UnLtd said: “I think women make great catalysts for change and through WSSE which is a relatively new initiative I’ve been developing with others, we have a growing network of more than 100 women change makers bringing diversity, experience and social and ethical perspectives to support and mentor others. Many of our members are from within The University of Manchester, UMIP has been a great exponent and supporter of ours and Alliance Manchester Business School are sponsoring mentor training for the group.”

Professor Vikas Shah co-president of TiE UK North and Visiting Professor (MIT Sloan, Lisbon) who has been a great champion and provider of mentoring to a number of campus based female entrepreneurs, including Dr Ruth Daniel of IPOW, said: “The University of Manchester has an impressive amount of hugely talented female leaders in all fields of science and the humanities, alongside the University itself being led by Professor Dame Nancy Rothwell, who is one of the most inspiring people you will ever meet! The University celebrates entrepreneurship as an engine of growth, and does so in an inclusive way – meaning that gender, ethnicity and so on simply do not play a part in your access to, or support from initiatives.  The huge success of female entrepreneurs and academics has though, without a doubt, created momentum to inspire many other women to follow in their footsteps, achieving really great things.”

We have also recently added our Innovation Optimiser to empower more of our campus innovators to develop and build their business. Our first RoadMap programme provides lean start-up style training to take a technology or research hypothesis into a venture. It too has seen a high participation rate from female innovators. Dr Laura Etchells, who leads the programme, said: “Through Optimiser we aim to increase the incidence and quality of start-ups arising from the University’s rich and diverse community and to make it easier to start your own business. We see more and more female entrepreneurs stepping into the arena, it’s important that we build wide and diverse teams to tackle social problems and build commercial success.”

Amongst the staff and student led projects supported so far includes a number of innovative social and technology business led by or featuring females in significant roles;-

Dr Magda Sibley – HiSolar Ltd, a social business providing an innovative hybrid lighting system that combines, within one element, daylighting and off grid solar powered LED lighting for heritage buildings and social housing

Ruth Daniel – IPOW is a ground-breaking Creative Entrepreneurial Programme that is empowering the world’s most marginalised communities to create sustainable income and social change through their creativity

Amy Win – 4Lunch Ltd was established to increase the confidence and employability of people using the power of food in increasing the health and wellbeing of communities, as well as creating genuine employment opportunities

Jenny Berry – Your Own Words is a poetry programme developed from Jenny’s research project which is currently run in a Manchester-based prison. Poetry is used in a therapeutic way to help prisoners to express themselves through creativity rather than physically

Drs Caroline Sanders, Sandra Bucci and Mrs Charlotte Stockton Powdrell – are all  co-directors  of ClinTouch an interactive and easy to use mobile phone app that provides an innovative new way of supporting people with psychosis, a serious mental health disorder that affects one in every 100 people

Helen Power – director of Levenshulme Market CIC , a social enterprise that was recently selected as one of only three finalists in the prestigious BBC Food and Farming Awards 2015 market category

Professor Joanna Neill – Professor of Psychopharmacology is developing b-neuro a contract research organisation providing cognition testing services for the pharmaceutical industry

Professor Anne Barton – Professor of Rheumatology has created Inspiral Healthcare which aims to develop better treatments and diagnostics for musculoskeletal conditions

Alison Edmonds – founder and director of EpicSteps CIC, set up to develop confidence, leadership, career awareness and social responsibility in children aged 10-12yrs

Dr Erinma Ochu MBE, Wellcome Trust Engagement Fellow is developing FarmLab, a pop up urban farm for Manchester as part of the European City of Science 2016

1 Source Phillips, K. (2014). How Diversity Makes Us Smarter. Obtained from the Internet at http://www.scientificamerican.com/article/how-diversity-makes-us-smarter/

Tony Walker

UMIP’s Tony Walker

 

University of Manchester research to pioneer next generation of skin treatments

Written by UMIP on . Posted in News

IP based on translational research led by Dr Catherine O’Neill and Professor Andrew McBain at The University of Manchester has been transferred into a new company. The venture, Skinbiotix limited, is being supported by OptiBiotix Health plc (AIM: OPTI). OptiBiotix is a leading life sciences business developing products to tackle obesity, high cholesterol and diabetes on a global scale. The agreement was negotiated on behalf of the University by its technology transfer office, UMIP.

Dr O’Neill and Professor McBain will continue to actively support the development of the technology. The company is built on ground-breaking discoveries on the human microbiome and its application to develop skin heath products. It will help create new product opportunities in large global markets including skincare, Health Care Acquired Infections and wound care.

Dr Catherine O’Neil, Senior Lecturer in Clinical Biochemistry at The Centre for Dermatological Research at the University commented: ”The agreement with OptiBiotix is a really important step for our research. There is huge potential that our technology will help create products that will have real impact on the treatment  of skin conditions. “

Stephen O’Hara, OptiBiotix’s Chief Executive Officer, commented: “We are pleased to announce the acquisition of skin health technology from The University of Manchester. This acquisition accelerates OptiBiotix’s strategic intent to grow the company by extending our platform technologies into new application areas where there are large global markets and an unmet need. We expect this venture will lead to new product and partnering opportunities and make a significant contribution to the Group over the coming years.”

Director of Operations at UMIP, Dr. Rich Ferrie commented, “We are delighted to have entered into this agreement with OptiBiotix, who we believe is the ideal partner to develop the ground-breaking skin health microbiome science developed by Dr Catherine O’Neill and Professor Andrew McBain. The signing of this agreement represents a pivotal moment towards the release of innovative and effective skin healthcare products.”

Untreated

Untreated

treated

Treated

 

The images show human skin which has been stained with a green dye to visualise a protein, critical to skins function as a barrier between the body and the environment. The level of this protein increases dramatically following treatment with a particular bacterium (compare ‘untreated’ with ‘treated’).

 

 

UMIP - REPUTATION AND VALUE THROUGH INTELLECTUAL PROPERTY®

Privacy Policy / Terms and Conditions / © Copyright 2015 The University of Manchester Intellectual Property / Created by HTP Digital Marketing Agency

The University of Manchester Intellectual Property ("UMIP") acts solely as agent for the University in relation to any matter relating to intellectual property ("IP") and know how created at the University. This is whether such IP is created by employees, students or others. UMIP does not represent anyone else in such matters. If anyone else requires advice in relation to such IP then they must take their own independent legal advice.